New pill could help immune system fight rare sarcomas
NCT ID NCT07014137
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 20 times
Summary
This study tests an experimental oral drug called ABSK043 in about 20 people with advanced angiogenic sarcomas (intimal sarcoma, head/neck angiosarcoma, or EHE). The drug blocks a protein called PD-L1 to help the immune system attack cancer cells. The main goal is to see if the drug shrinks tumors and to check its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN- Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.